Notochordal Cells
Regeneration
Notogen is a biotechnology company focused on treating back and neck dysfunction caused by spinal disc degeneration. Our lead product, NTG-101, is a targeted, non-surgical, non-cellular treatment for degenerative disc disease.
News Release
Nov
2018
13
Therapeutic Potential of NTG-101, a Single Dose Injectable Treatment for Degenerative Disc Disease, Demonstrated in Preclinical Large Animal Study Published in Nature Publishing Group's “Scientific Reports”
Oct
2017
24
Best Papers Focus on Disc Regeneration, Pelvic Incidence
Protein-Based, Non-Cellular Biologic
NTG-101 is a patented formulation that protects spinal discs from degeneration, induces disc regeneration, and resolves discogenic pain without the invasiveness and risks associated with surgery or cell therapy.
Preclinical & Commercially Scalable
As a non-cell-based drug candidate, the development of NTG-101 benefits from clearly defined regulatory and manufacturing pathways. It is undergoing additional development in advance of an IND submission and commencement of clinical trials.